TerminatedPHASE1, PHASE2NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Studying Chronic mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Asana BioSciences
- Principal Investigator
- Niranjan Rao, PhD, MDAsana BioSciences
- Intervention
- ASN002 Dose Escalation(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (14)
- Arizona Oncology, Tempe, Arizona, United States
- University of California, San Francisco, San Francisco, California, United States
- Winship Cancer Institute - Emory, Atlanta, Georgia, United States
- University of Michigan, Ann Arbor, Michigan, United States
- START - Midwest, Grand Rapids, Michigan, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Gabrail Cancer Center, Canton, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Hospital Universitario Austral, Buenos Aires, Derqui, Pilar, Argentina
- Instituto Alexander Fleming, Buenos Aires, Argentina
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02440685 on ClinicalTrials.gov